Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
At the heart of Vera Therapeutics鈥� 300-page disclosures lie questions any biotech investor must answer: is cash lasting through Phase 3, how are atacicept trials progressing, and when are executives selling stock? Sifting through those details in a traditional SEC browser can consume hours.
Stock Titan solves that problem. Our AI reads every Vera Therapeutics annual report 10-K, quarterly earnings report 10-Q filing, and 8-K material events, then highlights what matters: R&D expense trends, trial enrollment updates, and partnership clauses. Need real-time Vera Therapeutics Form 4 insider transactions? We alert you the moment a director files. Prefer plain English? The platform offers 鈥淰era Therapeutics SEC filings explained simply,鈥� turning footnotes on shelf registrations into clear bullet points.
Whether you鈥檙e tracking Vera Therapeutics insider trading Form 4 transactions, comparing segments in the Vera Therapeutics annual report 10-K simplified, or studying the Vera Therapeutics proxy statement executive compensation, every document appears seconds after it hits EDGAR. Use AI-driven keyword search to locate BK-virus antibody spend, export tables from the latest Vera Therapeutics quarterly earnings report 10-Q filing, or receive concise 鈥渦nderstanding Vera Therapeutics SEC documents with AI鈥� summaries for board decks. Stop scrolling through dense biotech jargon鈥攐ur platform delivers Vera Therapeutics earnings report filing analysis and Vera Therapeutics 8-K material events explained so you can focus on decisions, not document hunting.
Vera Therapeutics (Nasdaq: VERA) filed an 8-K announcing a new Sales Agreement with TD Securities (USA) LLC (TD Cowen) dated 5 Aug 2025. The arrangement establishes an at-the-market (ATM) equity program permitting the company to issue and sell up to $200 million of Class A common stock under its effective shelf registration statement (Form S-3, File No. 333-282861).
TD Cowen will act as sales agent and/or principal, executing ordinary-course, block or negotiated transactions on Nasdaq or other trading venues. The company will pay a commission of up to 3.0 % of gross proceeds. Vera is under no obligation to sell shares, and either party may terminate the agreement by written notice. The filing simultaneously terminates the prior Sales Agreement dated 3 Jun 2022.
The program enhances funding flexibility without adding debt but could create dilution and share-price overhang if the full $200 million capacity is utilized.
Vera Therapeutics (VERA) filed a Form 4 showing director Patrick G. Enright, through Longitude Prime Fund and Longitude Venture Partners IV, bought 250,000 Class A shares on 23鈥�24 Jun 2025 at weighted-average prices of $20.87鈥�$22.35, spending roughly $5.3 million. Post-transaction indirect holdings rise to 5,394,212 shares, an increase of about 4.9%. All trades were open-market purchases (code 'P'); no sales or derivatives were reported. Footnotes disclose price ranges and standard Section 16 disclaimers. The scale and direction of the trade suggest insider confidence, but the filing offers no strategic commentary.
FAQ
What is the current stock price of Vera Therapeutics (VERA)?
What is the market cap of Vera Therapeutics (VERA)?
